1. Scrip
  2. >>Business
  3. >>Earnings

Comirnaty Gives Booster Shot To Pfizer Q3 Sales

Vaccine Drives Revenues Up 130%

 
• By Alaric DeArment

The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.

While Pfizer Inc. continues to reap huge revenues from its BioNTech SE-partnered COVID-19 vaccine Comirnaty, prompting another increase in sales guidance, without that windfall the company’s third quarter performance was muted, with some key product lines showing weakness. The company highlighted pipeline programs that could be the next set of growth drivers, albeit there have been some speedbumps in its gene therapy programs.

The drug maker announced its third quarter sales and earnings on 2 November, reporting revenues of $24.1bn, a 130% increase over the comparable period of 2020. Of that figure, $13bn came from sales of Comirnaty, but even when excluding the mRNA vaccine revenues saw a 7% increase. The company expects the vaccine to have sales of $36bn in 2021, compared with the $33.5bn it forecast when releasing its second quarter earnings

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.